File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters

TitleA recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters
Authors
Issue Date2021
PublisherAmerican Association for the Advancement of Science. The Journal's web site is located at http://www.sciencemag.org/marketing/stm/
Citation
Science Translational Medicine, 2021, v. 13 n. 606, p. article no. eabg1143 How to Cite?
AbstractMultiple safe and effective vaccines that elicit immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary to respond to the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a protein subunit vaccine composed of spike ectodomain protein (StriFK) plus a nitrogen bisphosphonate-modified zinc-aluminum hybrid adjuvant (FH002C). StriFK-FH002C generated substantially higher neutralizing antibody titers in mice, hamsters, and cynomolgus monkeys than those observed in plasma isolated from COVID-19 convalescent individuals. StriFK-FH002C also induced both TH1- and TH2-polarized helper T cell responses in mice. In hamsters, StriFK-FH002C immunization protected animals against SARS-CoV-2 challenge, as shown by the absence of virus-induced weight loss, fewer symptoms of disease, and reduced lung pathology. Vaccination of hamsters with StriFK-FH002C also reduced within-cage virus transmission to unvaccinated, cohoused hamsters. In summary, StriFK-FH002C represents an effective, protein subunit-based SARS-CoV-2 vaccine candidate.
Persistent Identifierhttp://hdl.handle.net/10722/304524
ISSN
2023 Impact Factor: 15.8
2023 SCImago Journal Rankings: 6.510
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWu, Y-
dc.contributor.authorHuang, X-
dc.contributor.authorYuan, L-
dc.contributor.authorWang, S-
dc.contributor.authorZhang, Y-
dc.contributor.authorXiong, H-
dc.contributor.authorChen, R-
dc.contributor.authorMa, J-
dc.contributor.authorQi, R-
dc.contributor.authorNie, M-
dc.contributor.authorXu, J-
dc.contributor.authorZhang, Z-
dc.contributor.authorChen, L-
dc.contributor.authorWei, M-
dc.contributor.authorZhou, M-
dc.contributor.authorCai, M-
dc.contributor.authorShi, Y-
dc.contributor.authorZhang, L-
dc.contributor.authorYu, H-
dc.contributor.authorHong, J-
dc.contributor.authorWang, Z-
dc.contributor.authorHong, Y-
dc.contributor.authorYue, M-
dc.contributor.authorLi, Z-
dc.contributor.authorChen, D-
dc.contributor.authorZheng, Q-
dc.contributor.authorLi, S-
dc.contributor.authorChen, Y-
dc.contributor.authorCheng, T-
dc.contributor.authorZhang, J-
dc.contributor.authorZhang, T-
dc.contributor.authorZhu, H-
dc.contributor.authorZhao, Q-
dc.contributor.authorYuan, Q-
dc.contributor.authorGuan, Y-
dc.contributor.authorXia, N-
dc.date.accessioned2021-09-23T09:01:16Z-
dc.date.available2021-09-23T09:01:16Z-
dc.date.issued2021-
dc.identifier.citationScience Translational Medicine, 2021, v. 13 n. 606, p. article no. eabg1143-
dc.identifier.issn1946-6242-
dc.identifier.urihttp://hdl.handle.net/10722/304524-
dc.description.abstractMultiple safe and effective vaccines that elicit immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary to respond to the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a protein subunit vaccine composed of spike ectodomain protein (StriFK) plus a nitrogen bisphosphonate-modified zinc-aluminum hybrid adjuvant (FH002C). StriFK-FH002C generated substantially higher neutralizing antibody titers in mice, hamsters, and cynomolgus monkeys than those observed in plasma isolated from COVID-19 convalescent individuals. StriFK-FH002C also induced both TH1- and TH2-polarized helper T cell responses in mice. In hamsters, StriFK-FH002C immunization protected animals against SARS-CoV-2 challenge, as shown by the absence of virus-induced weight loss, fewer symptoms of disease, and reduced lung pathology. Vaccination of hamsters with StriFK-FH002C also reduced within-cage virus transmission to unvaccinated, cohoused hamsters. In summary, StriFK-FH002C represents an effective, protein subunit-based SARS-CoV-2 vaccine candidate.-
dc.languageeng-
dc.publisherAmerican Association for the Advancement of Science. The Journal's web site is located at http://www.sciencemag.org/marketing/stm/-
dc.relation.ispartofScience Translational Medicine-
dc.rightsScience Translational Medicine. Copyright © American Association for the Advancement of Science.-
dc.rightsThis is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in [Science Translational Medicine] on [Volume 13 and 2021], DOI: [10.1126/scitranslmed.abg1143].-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleA recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters-
dc.typeArticle-
dc.identifier.emailZhu, H: zhuhch@hku.hk-
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hk-
dc.identifier.authorityZhu, H=rp01535-
dc.identifier.authorityGuan, Y=rp00397-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1126/scitranslmed.abg1143-
dc.identifier.pmid34285130-
dc.identifier.scopuseid_2-s2.0-85113394391-
dc.identifier.hkuros325425-
dc.identifier.volume13-
dc.identifier.issue606-
dc.identifier.spagearticle no. eabg1143-
dc.identifier.epagearticle no. eabg1143-
dc.identifier.isiWOS:000686429000006-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats